| The diagnosis and clinical management of the neuropsychiatric manifestations of lupus M Govoni, A Bortoluzzi, M Padovan, E Silvagni, M Borrelli, F Donelli, ... Journal of autoimmunity 74, 41-72, 2016 | 198 | 2016 |
| Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study A Bettiol, ML Urban, L Dagna, V Cottin, F Franceschini, S Del Giacco, ... Arthritis & rheumatology 74 (2), 295-306, 2022 | 120 | 2022 |
| Focus on sex and gender: what we need to know in the management of rheumatoid arthritis B Maranini, A Bortoluzzi, E Silvagni, M Govoni Journal of personalized medicine 12 (3), 499, 2022 | 70 | 2022 |
| Peripheral nervous system involvement in systemic lupus erythematosus: a review of the evidence A Bortoluzzi, E Silvagni, F Furini, M Piga, M Govoni Clinical and experimental rheumatology 37 (1), 146-155, 2019 | 64 | 2019 |
| One year in review 2020: novelties in the treatment of rheumatoid arthritis E Silvagni, A Giollo, G Sakellariou, N Ughi, M D'Amico, C Scire, ... Clinical and experimental rheumatology 38 (2), 181-194, 2020 | 62 | 2020 |
| The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease A Abhishek, SK Tedeschi, T Pascart, A Latourte, N Dalbeth, T Neogi, ... Arthritis & Rheumatology 75 (10), 1703-1713, 2023 | 54 | 2023 |
| Peripheral nervous system involvement in systemic lupus erythematosus: a retrospective study on prevalence, associated factors and outcome A Bortoluzzi, M Piga, E Silvagni, E Chessa, A Mathieu, M Govoni Lupus 28 (4), 465-474, 2019 | 54 | 2019 |
| One year in review 2019: novelties in the treatment of rheumatoid arthritis E Silvagni, M Di Battista, A Bonifacio, D Zucchi, G Governato, C Scire Clinical and experimental rheumatology 37 (4), 519-534, 2019 | 40 | 2019 |
| Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health … E Silvagni, A Bortoluzzi, G Carrara, A Zanetti, M Govoni, CA Scirè BMJ open 8 (9), e021447, 2018 | 40 | 2018 |
| Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian … M Caprioli, G Carrara, G Sakellariou, E Silvagni, CA Scirè RMD open 3 (2), e000523, 2017 | 40 | 2017 |
| SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study D Saadoun, M Vieira, M Vautier, X Baraliakos, I Andreica, JAP da Silva, ... The Lancet Rheumatology 3 (7), e481-e488, 2021 | 38 | 2021 |
| Systemic lupus erythematosus: one year in review 2023 D Zucchi, E Silvagni, E Elefante, V Signorini, C Cardelli, F Trentin, ... Clinical and experimental rheumatology 41 (5), 997-1008, 2023 | 37 | 2023 |
| Rheumatoid arthritis and cardiovascular risk: retrospective matched-cohort analysis based on the RECORD study of the Italian Society for Rheumatology L Argnani, A Zanetti, G Carrara, E Silvagni, G Guerrini, A Zambon, ... Frontiers in medicine 8, 745601, 2021 | 37 | 2021 |
| Factors associated with fertility abnormalities in women with systemic lupus erythematosus: a systematic review and meta-analysis S Giambalvo, C Garaffoni, E Silvagni, F Furini, R Rizzo, M Govoni, ... Autoimmunity Reviews 21 (4), 103038, 2022 | 34 | 2022 |
| Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease … G Carrara, A Bortoluzzi, G Sakellariou, E Silvagni, A Zanetti, M Govoni, ... Clinical and experimental rheumatology 37 (1), 60-66, 2019 | 34 | 2019 |
| One year in review 2018: novelties in the treatment of rheumatoid arthritis A Bortoluzzi, F Furini, E Generali, E Silvagni, N Luciano, C Scire Clinical and experimental rheumatology 36 (3), 0347-0361, 2018 | 34 | 2018 |
| Novel insights into the management of rheumatoid arthritis: one year in review 2022 C Garaffoni, A Adinolfi, A Bortoluzzi, G Filippou, A Giollo, G Sakellariou, ... Clinical and experimental rheumatology 40 (7), 1247-1257, 2022 | 32 | 2022 |
| From bed to bench and back: TNF-α, IL-23/IL-17A, and JAK-dependent inflammation in the pathogenesis of psoriatic synovitis E Silvagni, S Missiroli, M Perrone, S Patergnani, C Boncompagni, ... Frontiers in Pharmacology 12, 672515, 2021 | 27 | 2021 |
| Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept. E Generali, G Carrara, C Selmi, SMM Verstappen, A Zambon, A Bortoluzzi, ... Clinical and Experimental Rheumatology 36 (2), 310-313, 2017 | 25 | 2017 |
| Biological and synthetic target DMARDs in psoriatic arthritis E Silvagni, A Bortoluzzi, G Ciancio, M Govoni Pharmacological Research 149, 104473, 2019 | 19 | 2019 |
